GlaxoSmithKline Encouraged By Blood-Cancer Drug Study
December 12 2017 - 02:56AM
Dow Jones News
By Adam Clark
GlaxoSmithKline PLC (GSK.LN) said Tuesday that it has generated
promising new data from a study of a potential treatment for
multiple myeloma, a cancer that affects blood cells in bone
marrow.
The drug company said new data from the dose-expansion phase of
its phase 1/2 study of GSK2857916 demonstrated a 60% response rate
and median progression-free survival of 7.9 months in patients who
had been heavily pre-treated.
GlaxoSmithKline said it was encouraged by the response rate seen
in patients who had very limited options for further treatment. The
company said it intends to rapidly progress development of the
treatment, initiating pivotal monotherapy and new combination
studies in 2018.
Write to Adam Clark at adam.clark@dowjones.com;
@AdamDowJones
(END) Dow Jones Newswires
December 12, 2017 02:41 ET (07:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024